347 related articles for article (PubMed ID: 26977882)
1. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
Pei Y; Liu KW; Wang J; Garancher A; Tao R; Esparza LA; Maier DL; Udaka YT; Murad N; Morrissy S; Seker-Cin H; Brabetz S; Qi L; Kogiso M; Schubert S; Olson JM; Cho YJ; Li XN; Crawford JR; Levy ML; Kool M; Pfister SM; Taylor MD; Wechsler-Reya RJ
Cancer Cell; 2016 Mar; 29(3):311-323. PubMed ID: 26977882
[TBL] [Abstract][Full Text] [Related]
2. Targeting HDAC And PI3K Inhibits MYC-Driven Medulloblastoma Growth.
Cancer Discov; 2016 May; 6(5):OF10. PubMed ID: 27012830
[TBL] [Abstract][Full Text] [Related]
3. An animal model of MYC-driven medulloblastoma.
Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
[TBL] [Abstract][Full Text] [Related]
4. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
5. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
6. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
Ecker J; Oehme I; Mazitschek R; Korshunov A; Kool M; Hielscher T; Kiss J; Selt F; Konrad C; Lodrini M; Deubzer HE; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
Acta Neuropathol Commun; 2015 Apr; 3():22. PubMed ID: 25853389
[TBL] [Abstract][Full Text] [Related]
7. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
8. Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
[TBL] [Abstract][Full Text] [Related]
9. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
10. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
11. Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem Cells.
Xue Y; Fu Y; Zhao F; Gui G; Li Y; Rivero-Hinojosa S; Liu G; Li Y; Xia S; Eberhart CG; Ying M
Mol Cancer Ther; 2021 Jun; 20(6):1199-1209. PubMed ID: 33722850
[TBL] [Abstract][Full Text] [Related]
12. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Liu T; Tee AE; Porro A; Smith SA; Dwarte T; Liu PY; Iraci N; Sekyere E; Haber M; Norris MD; Diolaiti D; Della Valle G; Perini G; Marshall GM
Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18682-7. PubMed ID: 18003922
[TBL] [Abstract][Full Text] [Related]
13. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
Valinciute G; Ecker J; Selt F; Hielscher T; Sigaud R; Ridinger J; Thatikonda V; Gatzweiler C; Robinson S; Talbot J; Bernardi F; Picard D; Blattner-Johnson M; Schmid S; Jones DT; van Tilburg CM; Capper D; Kool M; Remke M; Oehme I; Pfister SM; Roussel MF; Ayrault O; Witt O; Milde T
J Neurooncol; 2023 May; 163(1):143-158. PubMed ID: 37183219
[TBL] [Abstract][Full Text] [Related]
14. HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma.
da Cunha Jaeger M; Ghisleni EC; Cardoso PS; Siniglaglia M; Falcon T; Brunetto AT; Brunetto AL; de Farias CB; Taylor MD; Nör C; Ramaswamy V; Roesler R
J Mol Neurosci; 2020 Jun; 70(6):981-992. PubMed ID: 32056089
[TBL] [Abstract][Full Text] [Related]
15. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
17. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Milde T; Lodrini M; Savelyeva L; Korshunov A; Kool M; Brueckner LM; Antunes AS; Oehme I; Pekrun A; Pfister SM; Kulozik AE; Witt O; Deubzer HE
J Neurooncol; 2012 Dec; 110(3):335-48. PubMed ID: 23054560
[TBL] [Abstract][Full Text] [Related]
18. Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.
Simmons JK; Michalowski AM; Gamache BJ; DuBois W; Patel J; Zhang K; Gary J; Zhang S; Gaikwad S; Connors D; Watson N; Leon E; Chen JQ; Kuehl WM; Lee MP; Zingone A; Landgren O; Ordentlich P; Huang J; Mock BA
Mol Cancer Ther; 2017 Sep; 16(9):2008-2021. PubMed ID: 28522584
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
[TBL] [Abstract][Full Text] [Related]
20. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
